GeneDx Holdings Debt to Equity Ratio 2020-2025 | WGS
Current and historical debt to equity ratio values for GeneDx Holdings (WGS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. GeneDx Holdings debt/equity for the three months ending March 31, 2025 was 0.20.
| GeneDx Holdings Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.19B | $0.26B | 0.73 |
| 2024-12-31 | $0.17B | $0.25B | 0.71 |
| 2024-09-30 | $0.20B | $0.21B | 1.00 |
| 2024-06-30 | $0.20B | $0.19B | 1.01 |
| 2024-03-31 | $0.19B | $0.21B | 0.90 |
| 2023-12-31 | $0.19B | $0.23B | 0.84 |
| 2023-09-30 | $0.16B | $0.25B | 0.64 |
| 2023-06-30 | $0.18B | $0.30B | 0.61 |
| 2023-03-31 | $0.22B | $0.33B | 0.66 |
| 2022-12-31 | $0.24B | $0.25B | 0.94 |
| 2022-09-30 | $0.27B | $0.56B | 0.48 |
| 2022-06-30 | $0.30B | $0.64B | 0.46 |
| 2022-03-31 | $0.19B | $0.33B | 0.57 |
| 2021-12-31 | $0.17B | $0.39B | 0.43 |
| 2021-09-30 | $0.21B | $0.39B | 0.54 |
| 2021-06-30 | $0.44B | $0.01B | 87.64 |
| 2021-03-31 | $0.44B | $0.01B | 87.74 |
| 2020-12-31 | $0.00B | 0.00 | |
| 2020-09-30 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $1.997B | $0.305B |
| GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $135.390B | 25.39 |
| Elevance Health (ELV) | United States | $84.947B | 10.96 |
| CVS Health (CVS) | United States | $77.596B | 9.64 |
| Cencora (COR) | United States | $56.866B | 19.78 |
| DiDi Global (DIDIY) | China | $22.921B | 34.79 |
| Natera (NTRA) | United States | $21.460B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.549B | 13.28 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.465B | 0.00 |
| CochLear (CHEOY) | Australia | $11.562B | 0.00 |
| Revvity (RVTY) | United States | $10.871B | 18.71 |
| ICON (ICLR) | Ireland | $10.610B | 9.86 |
| Viatris (VTRS) | United States | $10.094B | 3.47 |
| Doximity (DOCS) | United States | $9.727B | 45.30 |
| Avantor (AVTR) | United States | $8.961B | 13.02 |
| HealthEquity (HQY) | United States | $8.748B | 43.04 |
| Medpace Holdings (MEDP) | United States | $8.582B | 22.79 |
| Sonic Healthcare (SKHHY) | Australia | $8.220B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.810B | 13.35 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 27.18 |
| Bausch + Lomb (BLCO) | Canada | $4.171B | 24.58 |
| BrightSpring Health Services (BTSG) | United States | $4.074B | 37.71 |
| Sotera Health (SHC) | United States | $3.528B | 20.05 |
| Surgery Partners (SGRY) | United States | $2.954B | 38.42 |
| Alignment Healthcare (ALHC) | United States | $2.920B | 0.00 |
| Concentras Parent (CON) | United States | $2.761B | 15.96 |
| Organon (OGN) | United States | $2.376B | 2.52 |
| Ardent Health Partners (ARDT) | United States | $2.127B | 9.07 |
| Premier (PINC) | United States | $1.896B | 14.39 |
| Progyny (PGNY) | United States | $1.765B | 38.85 |
| PACS (PACS) | United States | $1.558B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.368B | 27.36 |
| Teladoc Health (TDOC) | United States | $1.242B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.190B | 9.05 |
| Establishment Labs Holdings (ESTA) | $1.067B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| CareDx (CDNA) | United States | $0.982B | 15.33 |
| Agilon Health (AGL) | United States | $0.923B | 0.00 |
| Nutex Health (NUTX) | United States | $0.911B | 13.77 |
| AMN Healthcare Services Inc (AMN) | United States | $0.822B | 7.70 |
| QDM (QDMI) | Hong Kong, SAR China | $0.743B | 0.00 |
| Embecta (EMBC) | United States | $0.658B | 4.43 |
| InnovAge Holding (INNV) | United States | $0.545B | 0.00 |
| Enhabit (EHAB) | United States | $0.529B | 43.54 |
| LifeMD (LFMD) | United States | $0.524B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.484B | 10.90 |
| SBC Medicals (SBC) | United States | $0.477B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.471B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.400B | 0.00 |
| Oncology Institute (TOI) | United States | $0.269B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.220B | 0.00 |
| Beauty Health (SKIN) | United States | $0.213B | 0.00 |
| KindlyMD (NAKA) | United States | $0.151B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.142B | 23.17 |
| OncoCyte (OCX) | United States | $0.093B | 0.00 |
| So-Young (SY) | China | $0.090B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.063B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.063B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Biodesix (BDSX) | United States | $0.051B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.038B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.020B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |